Hyperuricemia is a common metabolic disease caused by abnormally high levels of uric acid (UA), which results from excessive uric acid production or inadequate renal excretion, and can progressively lead to severe kidney damage. In this study, an oral microsphere strategy (Eug/Lut@HAMA) was developed for the potential treatment of hyperuricemia-related kidney injury by encapsulating Euglena (Eug) and luteolin (Lut) in methacrylated hyaluronic acid (HAMA) microspheres. Eug has UA adsorption capabilities, Lut helps reduce UA formation, and HAMA microspheres have adhesive properties. Eug/Lut@HAMA can effectively lower UA levels.And provides protective effects against UA-induced reactive oxygen species generation and cell apoptosis. The microspheres showed reduced gastric drug loss, prolonged intestinal retention time, and sustained release of Eug and Lut. Eug and Lut exhibit complementary effects in the treatment of acute/chronic hyperuricemia, with Eug increasing UA excretion and Lut reducing UA production. Eug/Lut@HAMA offers multiple benefits in improving kidney injury, including anti-inflammatory, antioxidant, and anti-fibrotic properties. Additionally, Eug/Lut@HAMA has demonstrated long-term biosafety for oral administration. This study proposes a novel, effective, and safe approach to managing acute/chronic hyperuricemia with kidney injury by reducing UA production and enhancing UA excretion.

Original link

Microalgae-based drug delivery microspheres for treatment of hyperuricemia with renal injury

Pub Date : 2025-01-05

DOI: 10.1016/j.nantod.2024.102607

Xiaoyang Liu,  Jia Dong,  Jiarong Cui,  Yixin Zheng,  Huiqun Hu,  Ruoxi Wang,  Kaiyue Wang,  Danni Zhong,  Hui Huang,  Yichun Zheng,  Min Zhou